Simultaneous determination of L-702,007, a HIV-1 reverse transcriptase inhibitor, and its 6-hydroxy metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection

  • J Chromatogr A. 1996 Apr 5;729(1-2):211-7. doi: 10.1016/0021-9673(95)01011-4.
E J Woolf  1 ,  B Matuszewski
Affiliations
  • 1. Merck Research Laboratories, Department of Drug Metabolism, West Point, PA 19486, USA.
PMID: 9004942 DOI: 10.1016/0021-9673(95)01011-4
Abstract

A method for the determination of L-702,007, a human immunodeficiency virus type 1 Reverse Transcriptase Inhibitor, and its 6-hydroxy metabolite in human plasma is described. Plasma samples are extracted using phenyl solid-phase extraction columns. The extract is analyzed by HPLC using a column-switching system to remove interferences from late-eluting endogenous components. Fluorescence detection at an excitation wavelength of 314 nm and an emission wavelength of 390 nm is utilized. The assay was validated in the concentration range of 10-200 ng/ml when 1-ml aliquots of plasma were extracted. The assay has been used to support human pharmacokinetic studies.

Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-120737
    L-702007
    HIV-1 Reverse Transcriptase Inhibitor
    target: HIV
    Research Areas: Infection